-
Product Insights
PM-3 CAA Field, Malaysia – Vietnam PM-3 Commercial Arrangement Area
PM-3 CAA upstream field is located in South China Sea, Malaysia - Vietnam PM-3 Commercial Arrangement Area. The upstream field is owned by Hibiscus Petroleum Bhd (35%); PETRONAS Carigali International Sdn Bhd (35%); PetroVietnam Exploration Production Corp (30%). It is operated by Hibiscus Petroleum Bhd. The project started its operations in 1997. PM-3 CAA Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Melanoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in MelanomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell renal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Leiomyosarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in LeiomyosarcomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell renal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Liposarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in LiposarcomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell renal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-8002 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PM-8002 in Ovarian Cancer Drug Details: PM-8002 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-8002 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PM-8002 in Cervical Cancer Drug Details: PM-8002 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-8003 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PM-8003 in Solid Tumor Drug Details: PM-8003 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-534 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PM-534 in Solid Tumor Drug Details: PM-534 is under development for the treatment of advanced solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-1015 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PM-1015 in Solid Tumor Drug Details: PM-1015 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Prostate Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Prostate CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Cervical CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Pancreatic CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Gastric CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Endometrial Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Endometrial CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Ewing Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Ewing SarcomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Esophageal CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Peritoneal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Peritoneal CancerDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Synovial Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Synovial SarcomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Ductal Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Ductal CarcinomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear cell...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PM-54 in Renal Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PM-54 in Renal Cell CarcinomaDrug Details:PM-54 is under development for the treatment of urothelial carcinoma, clear...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.